Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 4/2020

01-10-2020 | Premature Rupture of Membranes | Original Article

Relationship between serum cystatin C level and pregnancy complications and abnormal glucose tolerance at 6-week postpartum in patients with gestational diabetes mellitus

Authors: Xiaoxia Tang, Hongfang Ju, Lili Yang, Chiwen Liu

Published in: International Journal of Diabetes in Developing Countries | Issue 4/2020

Login to get access

Abstract

Objective

This study aimed to investigate the relationship between serum cystatin C level and pregnancy complications and abnormal glucose tolerance at 6-week postpartum in patients with gestational diabetes mellitus (GDM).

Methods

Clinical data of 298 cases of GDM delivered in Taizhou People’s Hospital from January 2017 to June 2018 were retrospectively analyzed. According to the level of cystatin C before delivery, they were divided into normal group (≤ 1.1 mg/L) and elevated group (> 1.1 mg/L). The general situation, complications of pregnancy, and the incidence of abnormal glucose tolerance at 6 weeks after delivery were compared between the two groups. According to concomitant gestational hypertension in late pregnancy, the patients were divided into group A (GDM with hypertensive disorder complicating pregnancy (HDCP)) and group B (GDM without HDCP). The differences of age, parity, body mass index (BMI) and mean arterial pressure (MAP) in the first trimester of pregnancy, levels of cystatin C, creatinine, urinary microalbumin, and glycosylated hemoglobin in 24-week gestation and before delivering were compared between the two groups.

Results

There was no significant difference in age and parity between the normal group and the elevated group (p > 0.05). The levels of BMI (25.06 ± 3.46 vs 26.34 ± 3.65 kg/m2), creatinine (38.76 ± 16.52 vs 59.75 ± 17.82 mmol/L), and urinary microalbumin (37.11 ± 49.20 vs 61.25 ± 43.52 mg/L) and the incidence of premature delivery (9.35% vs 17.8%), premature rupture of membranes (11.22% vs 20.94%), and abnormal glucose tolerance at 6-week postpartum (18.69% vs 42.93%) in the normal group of cystatin C were significantly lower than that in the elevated group of cystatin C (p < 0.05). There was no significant difference in the incidence of hypertension (8.41% vs 7.85%) and oligohydramnios (33.64% vs 24.61%) between the two groups (p > 0.05). The clinical characteristics of group A (GDM with HDCP) and group B (GDM without HDCP) were compared. The results showed that the levels of age, BMI, and mean arterial pressure (MAP) were significantly different (p < 0.001). The results of binary logistic regression analysis showed that the significance value of MAP was 0.005 after controlling age factors, which indicated that MAP was an independent risk factor of GDM with HDCP, and the OR value of MAP was 1.420 (1.109–1.817).

Conclusion

The increase of cystatin C in patients with GDM does not increase the risk of HDCP, but it does increase the risks of premature delivery, PROM, and abnormal glucose tolerance at 6-week postpartum. Cystatin C is a biological index that may be valuable in predicting the occurrence of these diseases in GDM patients. The independent risk factor of GDM complicating HDCP is MAP.
Literature
1.
go back to reference Sun WJ, Yang HX. Maternal and fetal outcomes in pregnant women with abnormal glucose metabolism. Zhonghua Fu Chan Ke Za Zhi. 2007;42(6):377–81 Chinese.PubMed Sun WJ, Yang HX. Maternal and fetal outcomes in pregnant women with abnormal glucose metabolism. Zhonghua Fu Chan Ke Za Zhi. 2007;42(6):377–81 Chinese.PubMed
2.
go back to reference Bjornstad P, Cherney DZI. Kidney function can predict pregnancy outcomes. Clin J Am Soc Nephrol. 2017;12:1029–31.CrossRef Bjornstad P, Cherney DZI. Kidney function can predict pregnancy outcomes. Clin J Am Soc Nephrol. 2017;12:1029–31.CrossRef
3.
go back to reference Nevis IF, Reitsma A, Dominic A, McDonald S, Thabane L, Akl EA, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol. 2011;6:2587–98.CrossRef Nevis IF, Reitsma A, Dominic A, McDonald S, Thabane L, Akl EA, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol. 2011;6:2587–98.CrossRef
4.
go back to reference Piccoli GB, Attini R, Vasario E, Conijn A, Biolcati M, D’Amico F, et al. Pregnancy and chronic kidney disease: a challenge in all CKD stages. Clin J Am Soc Nephrol. 2010;5:844–55.CrossRef Piccoli GB, Attini R, Vasario E, Conijn A, Biolcati M, D’Amico F, et al. Pregnancy and chronic kidney disease: a challenge in all CKD stages. Clin J Am Soc Nephrol. 2010;5:844–55.CrossRef
5.
go back to reference Bellos I, Fitrou G, Daskalakis G, Papantoniou N, Pergialiotis V. Serum cystatin-c as predictive factor of preeclampsia: a meta-analysis of 27 observational studies. Pregnancy Hypertens. 2019 Apr;16:97–104.CrossRef Bellos I, Fitrou G, Daskalakis G, Papantoniou N, Pergialiotis V. Serum cystatin-c as predictive factor of preeclampsia: a meta-analysis of 27 observational studies. Pregnancy Hypertens. 2019 Apr;16:97–104.CrossRef
6.
go back to reference Risch M, Purde MT, Baumann M, Mohaupt M, Mosimann B, Renz H, et al. High first-trimester maternal blood cystatin C levels despite normal serum creatinine predict pre-eclampsia in singleton pregnancies. Scand J Clin Lab Invest. 2017 Dec;77(8):634–43.CrossRef Risch M, Purde MT, Baumann M, Mohaupt M, Mosimann B, Renz H, et al. High first-trimester maternal blood cystatin C levels despite normal serum creatinine predict pre-eclampsia in singleton pregnancies. Scand J Clin Lab Invest. 2017 Dec;77(8):634–43.CrossRef
7.
go back to reference Niraula A, Lamsal M, Baral N, et al. Combination of NGAL and Cystatin C for prediction of preeclampsia at 10–14 weeks of gestation. Clin Lab. 2019;65(5). Niraula A, Lamsal M, Baral N, et al. Combination of NGAL and Cystatin C for prediction of preeclampsia at 10–14 weeks of gestation. Clin Lab. 2019;65(5).
8.
go back to reference Thilaganathan B, Ralph E, Papageorghiou AT, Melchiorre K, Sheldon J. Raised maternal serum cystatin C: an early pregnancy marker for preeclampsia. Reprod Sci. 2009;16(8):788–93.CrossRef Thilaganathan B, Ralph E, Papageorghiou AT, Melchiorre K, Sheldon J. Raised maternal serum cystatin C: an early pregnancy marker for preeclampsia. Reprod Sci. 2009;16(8):788–93.CrossRef
9.
go back to reference Franceschini N, Qiu C, Barrow DA, Williams MA. Cystatin C and preeclampsia: a case control study. Ren Fail. 2008;30(1):89–95.CrossRef Franceschini N, Qiu C, Barrow DA, Williams MA. Cystatin C and preeclampsia: a case control study. Ren Fail. 2008;30(1):89–95.CrossRef
10.
go back to reference Yarcı GA, Tasci Y, Hatice C, et al. The prognostic value of first-trimester cystatin C levels for gestational complications. J Perinat Med. 2016;44(3):295–9. Yarcı GA, Tasci Y, Hatice C, et al. The prognostic value of first-trimester cystatin C levels for gestational complications. J Perinat Med. 2016;44(3):295–9.
11.
go back to reference Yalcin S, Ulas T, Eren MA, et al. Relationship between oxidative stress parameters and cystatin C levels in patients with severe preeclampsia. Medicina (Kaunas). 2013;49:118–23. Yalcin S, Ulas T, Eren MA, et al. Relationship between oxidative stress parameters and cystatin C levels in patients with severe preeclampsia. Medicina (Kaunas). 2013;49:118–23.
12.
go back to reference Zhao W, Pan J, Li H, Huang Y, Liu F, Tao M, et al. Relationship between high serum cystatin C levels and the risk of gestational diabetes mellitus. PLoS One. 2016;11(2):e0147277.CrossRef Zhao W, Pan J, Li H, Huang Y, Liu F, Tao M, et al. Relationship between high serum cystatin C levels and the risk of gestational diabetes mellitus. PLoS One. 2016;11(2):e0147277.CrossRef
13.
go back to reference Uruska A, Araszkiewicz A, Zozulinska-Ziolkiewicz D, et al. Does serum cystatin C level reflect insulin resistance in patients with type 1 diabetes? Clin Biochem. 2014;47(13–14):1235–8.CrossRef Uruska A, Araszkiewicz A, Zozulinska-Ziolkiewicz D, et al. Does serum cystatin C level reflect insulin resistance in patients with type 1 diabetes? Clin Biochem. 2014;47(13–14):1235–8.CrossRef
14.
go back to reference Reutens AT, Bonnet F, Lantieri O, Roussel R, Balkau B, For the data from an epidemiological study on the insulin resistance syndrome study group. Epidemiological study on the insulin resistance syndrome study group. The association between cystatin C and incident type 2 diabetes is related to central adiposity. Nephrol Dial Transplant. 2013;28(7):1820–9.CrossRef Reutens AT, Bonnet F, Lantieri O, Roussel R, Balkau B, For the data from an epidemiological study on the insulin resistance syndrome study group. Epidemiological study on the insulin resistance syndrome study group. The association between cystatin C and incident type 2 diabetes is related to central adiposity. Nephrol Dial Transplant. 2013;28(7):1820–9.CrossRef
15.
go back to reference Lee SH, Parka SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010;59(2):241–6.CrossRef Lee SH, Parka SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010;59(2):241–6.CrossRef
16.
go back to reference Curhan G. Cystatin C: a marker of renal function or something more? Clin Chem. 2005;51:293–4.CrossRef Curhan G. Cystatin C: a marker of renal function or something more? Clin Chem. 2005;51:293–4.CrossRef
17.
go back to reference Wattanavaekin K, Kitporntheranunt M, Kreepala C. Cystatin C as a novel predictor of preterm labor in severe preeclampsia. Kidney Res Clin Pract. 2018 Dec;37(4):338–46.CrossRef Wattanavaekin K, Kitporntheranunt M, Kreepala C. Cystatin C as a novel predictor of preterm labor in severe preeclampsia. Kidney Res Clin Pract. 2018 Dec;37(4):338–46.CrossRef
18.
go back to reference Chad L, Miriam M, Wolfgang K, Frank R. Association of maternal uric acid and cystatin C serum concentrations with maternal and neonatal cardiovascular risk markers and neonatal body composition: the Ulm SPATZ Health Study. PLoS One. 2018;13(7). Chad L, Miriam M, Wolfgang K, Frank R. Association of maternal uric acid and cystatin C serum concentrations with maternal and neonatal cardiovascular risk markers and neonatal body composition: the Ulm SPATZ Health Study. PLoS One. 2018;13(7).
19.
go back to reference Wu LF, Liu DY, Huang XH, et al. Postpartum reclassification in women with gestational diabetes and analyzing the high risk factors associated with them. Zhonghua Fu Chan Ke Za Zhi. 2003;38(3):140–2 Chinese.PubMed Wu LF, Liu DY, Huang XH, et al. Postpartum reclassification in women with gestational diabetes and analyzing the high risk factors associated with them. Zhonghua Fu Chan Ke Za Zhi. 2003;38(3):140–2 Chinese.PubMed
20.
go back to reference Yinchuan L, Zhenjuan T, Qing T, et al. Analysis of postpartum follow-up results of pregnant women with abnormal glucose tolerance. Chin J Pract Gynecol Obstet. 2007;23(12):960–2 Chinese. Yinchuan L, Zhenjuan T, Qing T, et al. Analysis of postpartum follow-up results of pregnant women with abnormal glucose tolerance. Chin J Pract Gynecol Obstet. 2007;23(12):960–2 Chinese.
21.
go back to reference Yogev Y, Langer O, Brustman L, Rosenn B. Pre-eclampsia and gestational diabetes mellitus: does a correlation exist early in pregnancy? J Matern Fetal Neonatal Med. 2004;15(1):39–43.CrossRef Yogev Y, Langer O, Brustman L, Rosenn B. Pre-eclampsia and gestational diabetes mellitus: does a correlation exist early in pregnancy? J Matern Fetal Neonatal Med. 2004;15(1):39–43.CrossRef
Metadata
Title
Relationship between serum cystatin C level and pregnancy complications and abnormal glucose tolerance at 6-week postpartum in patients with gestational diabetes mellitus
Authors
Xiaoxia Tang
Hongfang Ju
Lili Yang
Chiwen Liu
Publication date
01-10-2020
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 4/2020
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-020-00839-y

Other articles of this Issue 4/2020

International Journal of Diabetes in Developing Countries 4/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.